Literature DB >> 1998495

Inhibition of infection with human immunodeficiency virus type 1 by sulfated gangliosides.

A Handa1, H Hoshino, K Nakajima, M Adachi, K Ikeda, K Achiwa, T Itoh, Y Suzuki.   

Abstract

Four kinds of gangliosides, namely GM1a, GD1a, GD1b and GT1b and their sulfated derivatives were examined for antiviral activities against human immunodeficiency virus type 1 and abilities to modulate CD4 antigen on the cell surface. The infection of human T cells with the virus was markedly inhibited by treatment with the sulfated gangliosides at a concentration of 10 micrograms/ml, while the non-sulfated gangliosides had only weak antiviral activities. The sulfated gangliosides completely inhibited syncytium formation induced by HIV-1 at 30 micrograms/ml. The CD4 antigen on the surface of T cells became hardly detectable after treatment with them. They did not damage cells, nor prolong the activated partial thromboplastin time at concentrations of up to 100 micrograms/ml, suggesting that they may have little side effect in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998495     DOI: 10.1016/s0006-291x(05)81191-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  Structures of sulfated oligosaccharides isolated from the respiratory mucins of a non-secretor (O, Le(a + b -)) patient suffering from chronic bronchitis.

Authors:  J M Lo-Guidice; H Herz; G Lamblin; Y Plancke; P Roussel; M Lhermitte
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

3.  Identification and mapping of functional domains on human T-cell lymphotropic virus type 1 envelope proteins by using synthetic peptides.

Authors:  Y Sagara; Y Inoue; H Shiraki; A Jinno; H Hoshino; Y Maeda
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.